Aridis Pharmaceuticals Inc (ARDS) Return on Equity ROE from the third quarter 2023 to third quarter 2022 and annually, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aridis Pharmaceuticals Inc   (NASDAQ: ARDS)

Aridis Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Aridis Pharmaceuticals Inc in the third quarter 2023?
Due to the lack of equity, it was not possible to calculate Aridis Pharmaceuticals Inc 's return on equity (ROE) in its third quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -1 -9 -29 -30 -29
Return On Equity (TTM) - - - - -
ARDS's Total Ranking # # # # #
Equity (TTM) in Millions -12 -15 -28 -24 -36
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to ARDS Management Effectiveness >> ARDS's 5 Years Annual ROE >> Compare ARDS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ARDS Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2017)
2018
Total Equity in Millions -24 -13 -9 4 -63
Y / Y Equity Change - - - - -
Net Income in Millions -30 -42 -22 -30 -25
Y / Y Net Income Change - - - - -
Return On Equity - - - -816.31 % -

Back to ARDS Management Effectiveness >> ARDS's 5 Years Annual ROE >> Compare ARDS ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ARDS's' Return on Equity at Yahoo Finance
ARDS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ARDS's Competitors
Subscribers only: Roe for Aridis Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for ARDS's Customers




Companies with similar Return On Equity at Sep 30 2023, within Healthcare Sector ROE
Haemonetics Corporation  15.43 %
Eton Pharmaceuticals Inc   15.41 %
Charles River Laboratories International inc   15.18 %
Stryker Corp  15.03 %
Alpha Pro Tech Ltd   14.19 %
Utah Medical Products Inc  14.15 %
Abbott Laboratories  13.84 %
Quest Diagnostics Inc  13.23 %
Intuitive Surgical Inc   13.14 %
Bio techne Corp  13.06 %
Puma Biotechnology Inc   12.75 %
Orasure Technologies Inc  12.63 %
Progyny Inc   11.64 %
Henry Schein Inc   11.27 %
Revelation Biosciences Inc   11.18 %
Universal Health Services Inc   11.05 %
Pfizer Inc  10.69 %
Merck and Co Inc   10.67 %
Neurocrine Biosciences Inc   10.54 %
Dynavax Technologies Corporation  10.46 %
Biogen Inc   10.42 %
U S Physical Therapy Inc  10.34 %
Pediatrix Medical Group Inc   10.08 %
Align Technology inc   9.99 %
The Pennant Group Inc   9.90 %
Fonar Corporation  9.83 %
Lemaitre Vascular Inc   9.78 %
Teleflex Incorporated  9.69 %
Incyte Corporation  9.19 %
Steris Plc  8.99 %

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.